Michael A. MSc, MBA
About Michael A. MSc, MBA
Michael A. is the Director of Global Market Access at Bristol Myers Squibb in Switzerland, with extensive experience in market access strategy, value communication, and strategic pricing in the biopharmaceutical industry.
Current Role at Bristol Myers Squibb
Michael A. is currently serving as the Director of Global Market Access at Bristol Myers Squibb in Switzerland. In this role, he is responsible for leading market access strategies, including value communication and strategic pricing. His work involves launching new products and managing the pipeline within the biopharmaceutical sector. He brings extensive experience in therapeutic areas such as oncology, hematology, and immunology to his current position.
Professional Experience at Roche
Michael previously worked at Roche where he held multiple roles. From 2012 to 2020, he served as the Global Market Access & Pricing Director in the Basel Area, Switzerland. During this period, he was involved in market access and pricing strategies for diseases like Crohn's disease, ulcerative colitis, and rheumatoid arthritis. Additionally, from 2011 to 2018, he held the position of Global Strategy / Strategic Insights Director at Roche, focusing on strategic planning and market insights.
Earlier Career and Strategy Consulting
Michael worked as a Strategy Consultant at a leading global strategy consulting firm from 2006 to 2012 in London, United Kingdom. Prior to this, he was the Commercial Director at Merck and MSD from 2003 to 2006, and a Scientist at Bayer Pharmaceuticals and Bayer Schering Pharma from 2000 to 2003 in the San Francisco Bay Area. His early career provided him with valuable experience in commercial roles and scientific research.
Educational Background
Michael holds an MBA from the University of Oxford, a Master's in Health Economics & Health Policy from The London School of Economics and Political Science (LSE), and a Master's in Cell & Molecular Biology from the University of California, Berkeley. He also earned a Bachelor of Science (BS) in Biochemistry from Imperial College London. His diverse educational background has equipped him with a strong foundation in business administration, health economics, and biochemistry.
Expertise and Therapeutic Areas
With a strong background in market access strategy, value communication, and strategic pricing, Michael has extensive expertise in health technology assessment (HTA) and value demonstration. He has been involved in the launch of new products and pipeline management, especially in therapeutic areas like oncology, hematology, inflammation, immunology, and rare diseases. Michael also has experience with cell therapy and CAR-T therapies, enhancing his comprehensive understanding of advanced therapeutic modalities.